Stealthy Ganymed gets €45m for 'ideal' Mabs in tricky solid tumors
This article was originally published in Scrip
The €45m that 80-person stealth company Ganymed Pharmaceuticals raised on 18 November from existing investors should take its lead compound through to the brink of Phase III completion in gastroesophageal cancer, but the company may still be looking to raise more money in order to leverage its compounds into US and Asia market. Ganymed, which had raised over €100m prior to this move, has been developing what it calls 'ideal' antibody products, those where the target is distributed widely on tumors but absent, or virtually absent from normal tissue.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.